Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma · line 3 · None
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 3 |
|---|---|
| Track | aggressive |
| Linked regimen | None |
| ID | IND-CLL-3L-LISOCEL |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-01 | pending_clinical_signoff |
| Diseases | DIS-CLL |
| Sources | SRC-ESMO-CLL-2024 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Aggressive-track 3L+ option for r/r double-exposed CLL/SLL (post-cBTKi + post-BCL-2i) per TRANSCEND CLL-004 — first CAR-T approval in CLL (FDA March 2024). Trial source SRC-TRANSCEND-CLL-004-SIDDIQI-2023 absent from KB at chunk authoring time — citing NCCN-BCELL-2025 + ESMO-CLL-2024 pending source-stub creation (flagged for trial-source ingest follow-up). Missing entity flag: dedicated REG- entity for CLL liso-cel not authored (recommended_regimen empty); lymphodepletion + dose mirrors DLBCL REGIMEN-LISOCEL-DLBCL-3L until CLL-specific regimen authored — flagged for REG follow-up. Pirtobrutinib (IND-CLL-3L-PIRTOBRUTINIB) is preferred non-CAR-T 3L alternative; sequencing driven by patient fitness, BTK-C481 mutation status, and access pathway.
Used By
No reverse references found in the YAML corpus.